A multicentre, multinational, randomised, double-blind, pilot, ascending dose for non responder, parallel group study on the therapeutic efficacy and safety of o.d. Zofenopril 30 mg plus HCTZ 12.5 mg vs. Irbersartan 150 mg plus HCTZ 12.5 mg in elderly subjects (age > 65 years) affected by Isolated Systolic Hypertension never treated or non responder to previous antihypertensive therapy (monotherapy or association of maximum two treatments).

Trial Profile

A multicentre, multinational, randomised, double-blind, pilot, ascending dose for non responder, parallel group study on the therapeutic efficacy and safety of o.d. Zofenopril 30 mg plus HCTZ 12.5 mg vs. Irbersartan 150 mg plus HCTZ 12.5 mg in elderly subjects (age > 65 years) affected by Isolated Systolic Hypertension never treated or non responder to previous antihypertensive therapy (monotherapy or association of maximum two treatments).

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2014

At a glance

  • Drugs Hydrochlorothiazide; Irbesartan; Zofenopril
  • Indications Isolated systolic hypertension
  • Focus Therapeutic Use
  • Sponsors Istituto Lusofarmaco
  • Most Recent Events

    • 26 Jul 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 23 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top